Rajab Idriss
Gastroenterology · Mobile, ALNPI 1184112856
Payments from drug & device makers
Across 110 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$483
- Madrigal Pharmaceuticals$321
- Gilead$310
- Takeda Pharmaceuticals U.S.A., Inc.$250
- Ipsen Biopharmaceuticals, Inc$214
- Intercept Pharmaceuticals, Inc.$150
- plus $900 from 19 others
What the payments were for
- Food & beverage$2,52996%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $483 |
| Madrigal Pharmaceuticals | 8 | $321 |
| Gilead | 16 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $250 |
| Ipsen Biopharmaceuticals, Inc | 9 | $214 |
| Intercept Pharmaceuticals, Inc. | 1 | $150 |
| Johnson & Johnson | 4 | $144 |
| Regeneron Healthcare Solutions, Inc. | 5 | $125 |
| Sanofi | 3 | $88 |
| Mahana Therapeutics, Inc. | 1 | $73 |
| Boston Scientific | 1 | $69 |
| Merck | 3 | $55 |
| Amgen | 3 | $54 |
| Pfizer | 2 | $46 |
| Bristol Myers Squibb | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| QOL Medical, LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $14 |
| Organon | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$2,628 in reported general payments places this provider in the 35th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 20 | $487,940 |
| XifaxanRifaximin | 53 | $216,757 |
| LinzessLinaclotide | 13 | $18,900 |
| Ursodiol | 75 | $15,726 |
| Tacrolimus | 15 | $3,843 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 42 | $2,657 |
| Lactulose | 49 | $1,819 |
| Mycophenolate Mofetil | 30 | $1,816 |
| Azathioprine | 21 | $1,478 |
| Nadolol | 20 | $1,262 |
| ConstuloseLactulose | 15 | $1,170 |
| Pantoprazole Sodium | 84 | $811 |
| Omeprazole | 42 | $707 |
| Carvedilol | 51 | $585 |
| Amiloride Hcl | 13 | $509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $310 | $487,94020 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $28 | $216,75753 claims |
| AbbVieLinzess | $483 | $18,90013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Mobile
- Jonathan SiegelMobile$2.6M
- Charles JohnsonMobile$1.2M
- Jack DipalmaMobile$958K
- Phillip HendersonMobile$462K
- William SonnierMobile$178K
- Jorge HerreraMobile$167K
- Matthew EvesMobile$46K
- John KirbyMobile$34K
- Michael SandersMobile$25K
- Cody BarnettMobile$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.